Final results and biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study

被引：1

作者：

Nakamura, A. ^{[1
]}

Kenmotsu, H. ^{[2
]}

Sakai, K. ^{[3
]}

Mori, K. ^{[4
]}

Kato, T. ^{[5
]}

Kirita, K. ^{[6
]}

Yoneshima, Y. ^{[7
]}

Azuma, K. ^{[8
]}

Nishino, K. ^{[9
]}

Teraoka, S. ^{[10
]}

Shukuya, T. ^{[11
]}

Masuda, K. ^{[12
]}

Hayashi, H. ^{[13
]}

Toyozawa, R. ^{[14
]}

Miura, S. ^{[15
]}

Fujimoto, D. ^{[16
]}

Nakagawa, K. ^{[13
]}

Yamamoto, N. ^{[17
]}

Nishio, K. ^{[18
]}

Takahashi, T. ^{[19
]}

机构：

[1] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[2] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[3] Kindai Univ, Dept Genome Biol, Fac Med, Osaka, Japan

[4] Shizuoka Canc Ctr, Clin Trial Coordinat Off, Shizuoka, Japan

[5] Kanagawa Canc Ctr, Thorac Oncol Dept, Yokohama, Kanagawa, Japan

[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[7] Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Japan

[8] Kurume Univ, Dept Internal Med, Kurume, Fukuoka, Japan

[9] OICI Osaka Int Canc Inst, Thorac Oncol Dept, Osaka, Japan

[10] Wakayama Med Univ, Resp Med & Med Oncol Dept, Wakayama, Japan

[11] Juntendo Univ Hosp, Dept Resp Med, Bunkyo, Japan

[12] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Med, Hiroshima, Japan

[13] Kindai Univ, Dept Med Oncol, Sch Med, Main Campus, Osaka, Japan

[14] Natl Hosp Org, Dept Thorac Oncol, Kyushu Canc Ctr, Fukuoka, Japan

[15] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[16] Kobe City Med Ctr, Resp Med, Gen Hosp, Kobe, Hyogo, Japan

[17] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[18] Kindai Univ, Dept Genome Biol, Sch Med, Main Campus, Osaka, Japan

[19] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1110

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

982P

引用

页码：S1000 / S1001

页数：2

共 50 条

[1] Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Kenmotsu, H.
Wakuda, K.
Mori, K.
Kato, T.
Sugawara, S.
Kirita, K.
Okamoto, I.
Azuma, K.
Nishino, K.
Teraoka, S.
Koyama, R.
Masuda, K.
Hayashi, H.
Toyozawa, R.
Miura, S.
Sato, Y.
Nakagawa, K.
Yamamoto, N.
Takahashi, T.
ANNALS OF ONCOLOGY, 2021, 32 : S1322 - S1323
[2] Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
Kenmotsu, Hirotsugu
Sakai, Kazuko
Mori, Keita
Kato, Terufumi
Sugawara, Shunichi
Kirita, Keisuke
Yoneshima, Yasuto
Azuma, Koichi
Nishino, Kazumi
Teraoka, Shunsuke
Koyama, Ryo
Masuda, Ken
Hayashi, Hidetoshi
Toyozawa, Ryo
Miura, Satoru
Sato, Yuki
Nakagawa, Kazuhiko
Yamamoto, Nobuyuki
Nishio, Kazuto
Takahashi, Toshiaki
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
[3] Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Kenmotsu, Hirotsugu
Wakuda, Kazushige
Mori, Keita
Kato, Terufumi
Sugawara, Shunichi
Kirita, Keisuke
Yoneshima, Yasuto
Azuma, Koichi
Nishino, Kazumi
Teraoka, Shunsuke
Shukuya, Takehito
Masuda, Ken
Hayashi, Hidetoshi
Toyozawa, Ryo
Miura, Satoru
Fujimoto, Daichi
Nakagawa, Kazuhiko
Yamamoto, Nobuyuki
Takahashi, Toshiaki
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : 1098 - 1108
[4] Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
Ko, Ryo
Shukuya, Takehito
Imamura, Chiyo K.
Tokito, Takaaki
Shimada, Naoko
Koyama, Ryo
Yamada, Kazuhiko
Ishii, Hidenobu
Azuma, Koichi
Takahashi, Kazuhisa
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 183 - +
[5] TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations
Yang, Yunpeng
Feng, Weineng
Jiang, Wei
Huang, Lu
Zhao, Yanqiu
Chen, Lili
Fang, Yong
Ji, Mei
Zhang, Tingting
Zhu, Junfei
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] A phase II study of osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L).
Wakuda, Kazushige
Yamaguchi, Hiroyuki
Kenmotsu, Hirotsugu
Fukuda, Minoru
Ebi, Noriyuki
Suetsugu, Takayuki
Inonue, Koji
Tanaka, Kentaro
Yokoyama, Toshihide
Kirita, Keisuke
Hataji, Osamu
Miura, Satoru
Chibana, Kenji
Yoshimura, Kenichi
Nakagawa, Kazuhiko
Yamamoto, Nobuyuki
Sugio, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation positive non-squamous non -small cell lung cancer: TORG1833.
Nakahara, Yoshiro
Kato, Terufumi
Isomura, Reiko
Seki, Nobuhiko
Furuya, Naoki
Naoki, Katsuhiko
Yamanaka, Takeharu
Okamoto, Hiroaki
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
Saito, Ryota
Sugawara, Shunichi
Ko, Ryo
Azuma, Koichi
Morita, Ryo
Maemondo, Makoto
Oizumi, Satoshi
Takahashi, Kazuhisa
Kagamu, Hiroshi
Tsubata, Yukari
Seike, Masahiro
Kikuchi, Toshiaki
Okamoto, Isamu
Satoshi, Morita
Asahina, Hajime
Tanaka, Kentaro
Sugio, Kenji
Kobayashi, Kunihiko
EUROPEAN JOURNAL OF CANCER, 2023, 185 : 83 - 93
[9] OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer
Yoh, Kiyotaka
Kato, Terufumi
Nakahara, Yoshiro
Isomura, Reiko
Misumi, Toshihiro
Tamiya, Motohiro
Furuya, Naoki
Ono, Akira
Takiguchi, Yuichi
Koyama, Kenichi
Ikeda, Satoshi
Watanabe, Kageaki
Tokito, Takaaki
Seki, Nobuhiko
Imai, Hisao
Shukuya, Takehito
Shibata, Yuji
Hosokawa, Shinobu
Kozuki, Toshiyuki
Okamoto, Hiroaki
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
Yoshida, Hironori
Kim, Young Hak
Sakamori, Yuichi
Nagai, Hiroki
Ozasa, Hiroaki
Kaneda, Toshihiko
Yoshioka, Hiroshige
Nakagawa, Hiroaki
Tomii, Keisuke
Okada, Asuka
Yoshimura, Kenichi
Hirabayashi, Masataka
Hirai, Toyohiro
ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987

← 1 2 3 4 5 →